Abbott Q3 Revenue Rises 14.5% to $13.0 Billion as GAAP EPS Falls

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

Abbott Laboratories ABT reported Q3 2026 revenue of $13.0B, up 14.5% YoY, beating estimates. However, it lowered its 2026 growth outlook due to a planned nutrition business spinoff. Nutrition and Diagnostics units performed well, while MedTech and Pharma segments underperformed. Adjusted EPS rose 9% YoY to $1.42, exceeding forecasts.

Abbott Laboratories (ABT) fell in premarket trading after reducing its 2026 growth outlook, despite Q3 revenue of $13.0B, up 14.5% YoY. The company plans to separate its nutrition business.

Abbott Laboratories (ABT) plans to spin off its nutrition business, which generates $8.5B in annual sales, into an independent company by late 2027. The new entity will include brands like Pedialyte and Similac, led by Daniel Salvadori. Abbott shares fell 3.9% premarket. The move aims to focus Abbott's core portfolio on medical devices and diagnostics, with no expected impact on 2026 or 2027 guidance.

Abbott reported a 3Q profit decline to $920M (53c/share) from $1.64B (94c/share) YoY, despite a 14% sales increase to $13.01B. Adjusted EPS of $1.42 met estimates. Diagnostics sales surged 47%, while operating costs rose 25%. Abbott expects full-year adjusted EPS of $5.50-$5.55 and 6% sales growth.

Abbott Laboratories plans to separate its nutrition business, generating $8.5B in annual sales, into an independent company by late 2027. Shares fell 3.9% premarket. The new company will include brands like Pedialyte and Similac, led by Daniel Salvadori. Abbott expects to incur one-time charges and maintain 2026 guidance. Post-separation, Abbott's sales will be around $42B.